Press Releases

Trial has met primary endpoints of safety and immunogenicity and secondary endpoint for efficacy based on response rate

Proceeds Will Fund Completion of GT-30 Trial of Personalized Therapeutic Cancer Vaccine in Liver Cancer

By RECIST1.1, Three Complete Responses and Seven Durable Partial Responses Achieved to Date--

Nomination Recognizes Progress and Promise of Geneos' Personalized Therapeutic Cancer Vaccines

Proceeds to Fund Expansion of Phase 1b/2a Trial of Personalized Therapeutic Cancer Vaccine in Liver Cancer

To Date, Four Patients Are Now Cancer Free Out of 23 Evaluable

Overall Response Rate 30.4 Percent in 23 Evaluable Patients Including Two Complete Responses and a Third Cancer-Free Patient

Encouraging Safety and Efficacy Data from Ongoing GT-30 Study in Second-Line HCC

Geneos expands its Phase Ib/IIa clinical trial in lead indication for treating patients with advanced hepatocellular carcinoma

Geneos Therapeutics announced positive preliminary results of its ongoing first-in-human trial. 

Texas-based GMP Plasmid CDMO VGXI, Inc. and Geneos Therapeutics, Inc. Expand their Clinical Manufacturing Supply Agreement in Support of Geneos’ Ongoing GT-30 Phase Ib/IIa Clinical Trial for advanced hepatocellular carcinoma (HCC)

Geneos Therapeutics has closed its Series A1 round, raising $12 million in financing.

VGXI, Inc., Geneos Therapeutics’ CDMO partner, completes manufacturing of first GMP Lot under Clinical Manufacturing Supply Agreement.

Geneos Therapeutics announced that its personalized neoantigen-targeting vaccine, GNOS-PV02 (based on its proprietary GT-EPIC™ platform), will be evaluated in a clinical trial for patients with advanced Hepatocellular Carcinoma (HCC).

VGXI and Geneos Therapeutics have entered into a long-term master supply agreement to establish small-scale and rapid turnaround production services ideally suited for the personalized therapy approach.